Collectively, our study suggests that ZLD1039 is a novel therapeutic agent for renal inflammation and fibrosis, with its specific molecular mechanism involving the up-regulation of LATS1 expression and the consequent inhibition of YAP activation. The gene discussed is LATS1; the disease is inflammatory response.